Status message

Not the entire site translated, but only to "Journal"

A randomized single-blind placebo controlled trial of Memantine, as addjunctive therapy for treatment of negative symptoms of paranoid schizophrenia

Osadshiy Yuriy, Archakov Danil,Tarakanova Elena,Voblenko Roman
Scientific and Production Association "Volgograd Center for disease prevention YugMed", Volgograd, Russia
Summary. This study analyzes the efficiency of memantine – an antagonist of N-methyl-D-aspartate receptors – as adjunctive therapy for the treatment of negative symptoms of paranoid schizophrenia. Fifty-two patients (30 males; age 20–50 years) were included with the diagnosis of F20.014 and F20.024 according to the international classification of diseases (version 10). The patients had been receiving neuroleptic monotherapy with a fixed dose for a period of at least 4 weeks prior to randomization. Clinical data were collected 8 weeks after memantine had been introduced as part of the treatment regimen. A patient was considered as responding to treatment if they a) scored 1-2 on the Clinical Global Impression Scale, and b) showed a greater than 25 % reduction of the total score on The Positive and Negative Syndrome Scale (PANSS) or a a greater than 20 % reduction on the negative subscale of PANSS. Forty-seven patients were randomized: treatment group (neuroleptic + memantine, n = 24, control group (neuroleptic + placebo, n = 23); 44 patients completed the study. Neither memantine nor placebo led to a reliable decrease of negative symptoms, and the groups did not differ from each other.
Contact: osadshiy@mail.ru

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat or click here to download the PDF file.

References: 

1.    Taylor D., Patton C., Kapur S. The Maudsley Prescribing Guidelines // Informa Healthcare. 10th edition. – 2009. – R. 47–48.
2.    Dzhons P.B., Bakli P.F. Shizofreniya. Klinicheskoe rukovodstvo / per. s angl.; pod obshch. red. S.N. Mosolova. – M., 2008.
3.    Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N .Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012.
4.    Mosolov S.N. Nekotorye aktual'nye teoreticheskie problemy diagnostiki, klassifikatsii, neirobiologii i terapii shizofrenii: sravnenie zarubezhnogo i otechestvennogo podkhodov // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. – 2010. – T. 110, № 6. – S. 4–11.
5.    Mosolov S.N., Kuzavkova M.V., Kalinin V.V., Eremin A.V., Sulimov G.Yu. Analiz vliyaniya atipichnykh antipsikhotikov na 5-faktornuyu model' shizofrenii // Sotsial'naya i klinicheskaya psikhiatriya. – 2003. – T. 13, № 3. – S. 45–51.
6.    Mosolov S.N. Sovremennaya antipsikhoticheskaya farmakoterapiya shizofrenii // Russkii meditsinskii zhurnal. – 2004. – T. 12, № 10. – S. 646–652.
7.    Mosolov S.N., Tsukarzi E.E., Kapiletti S.G. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M., 2012. – S. 11–61.
8.    Uribe E., Landaeta J., Wix R., Elben A. Memantine Reverses Social Withdrawal Induced by Ketamine in Rats // Exp Neurobiol. – 2013, Mar. – Vol. 22 (1). – R. 18–22. 
9.     Karlson A., Lekrub'e I. Dofaminovaya teoriya patogeneza shizofrenii. Rukovodstvo dlya vrachei / pod red. S.N. Mosolova. – London, 2004.    
10.    Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia // Neurosci Lett. –1980, Dec. – Vol. 20 (3). – R. 379–382. 
11.    Paparelli A., Forti M., Morrison P.D., Murray R.M. Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light // Frontiers in Behavioral Neuroscince. – 2011. – Vol. 5 (1). 
12.    Owley T., Salt J., Guter S. et al. A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders // Journal of Child and Adolescent Psychopharmacology. – 2006. – Vol. 16 (5). – R. 517–524.
13.    Erikson C., Posey D., Stigler K. et al. A retrospective study of memantine in children and adolescents with pervasive developmental disorders // Psychopharmacology. – 2007. – Vol. 191 (1). – R.141–147.
14.    Ghaleiha A., Asadabadi M., Mohammadi M. et al. Memantine as adjunctive treatment to risperidone in children with autistic disorder: A randomized, double-blind, placebo-controlled trial // International Journal of Neuropsychopharmacology. First view. – 2012. Vol. 1. – R. 1–7. 
15.    Carrey N., MacMaster F., Sparkes S. et al. Glutamatergic changes with treatment in attention deficit hyperactivity disorder: A preliminary case series // Journal of Child and Adolescent Psychopharmacology. – 2002. – Vol. 12 (4). – R. 331–336.
16.    Carrey N., MacMaster F., Gaudet L., Schmidt M. Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder // Journal of Child and Adolescent Psychopharmacology. – 2007. – Vol. 17 (1). – R. 11–17.
17.    Kavirajan H. Memantine: A comprehensive review of safety and efficacy // Drug Safety Evaluation. – 2009. – Vol. 8 (1). – R. 89–109.
18.    Hezel D., Beattie K., Stewart S. Memantine as an augmenting agent for severe pediatric OCD // American Journal of Psychiatry. – 2009. – Vol. 166 (2). – R. 237.
19.    Ghaleiha A., Entezari N., Modabbernia A. et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study // Journal of Psychiatric Research. – 2013. – Vol. 47 (2). – R. 175–180.
20.    Maeng S, Zarate C. The role of glutamate in mood disorders: Results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects //Current Psychiatry Reports. – 2007. – Vol. 9 (6). – R. 467–474.
21.    Ferguson J., Shingleton R. An open-label, flexible dose study of memantine in major depressive disorder // Clinical Neuropharmacology. – 2007. – Vol. 30 (3). – R. 136–144.
22.    Sani G., Serra G., Kotzalidis G. et al. The role of memantine in the treatment of psychiatric disorders other than the dementias: A review of current preclinical and clinical evidence // CNS Drugs. – 2012. – Vol. 26 (8). – R. 663–690. 
23.    Koukopoulos A., Reginaldi D., Serra G., Koukopoulos A.E., Sani G., Serra G. Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder // Bipolar Disorders. – 2010. – Vol. 12 (3). – R. 348–349.
24.    Koukopulos A., Serra G., Koukopoulos A.E., Serra G. The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: Findings from a 12-month naturalistic trial // Journal of Affective Disorders. – 2012. – Vol. 136 (1–2). – R. 163–166.
25.    Zdanys K., Tampi R. A systematic review of off-label uses of memantine for psychiatric disorders // Progress in Neuro-Psychopharmacology. – 2008. – Vol. 32 (6). – R. 1362–1374.
26.    Lieberman J., Papadakis K., Csernansky J. et al. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia // Neuropsychopharmacology. – 2009. – Vol. 34 (1). – R. 1322–1329.
27.    Koola M.M., Buchanan R.W., Pillai A. et al. Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia // Schizophr Res. – 2014. – Vol. 157 (0). – R. 84–89.
28.    Paraschakis A. Tackling Negative Symptoms of Schizophrenia with Memantine // Case Reports in Psychiatry. – 2014. – Article ID 384783. – 3 r.
29.    Swerdlow N.R., Bhakta S., Chou H. et al. Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis // Neuropsychopharmacology advance online publication. – 2015.
30.    Mosolov S.N., Smulevich A.B., Neznanov N.G. i dr. Primenenie agonistov mGLU2/3 – novyi podkhod k terapii shizofrenii: rezul'taty randomizirovannogo dvoinogo slepogo issledovaniya // Zhurnal nevrologii i psikhiatrii im. C.C. Korsakova. –2010. –T. 110, № 7. – S. 16–23.
31.    Krystal J.H., Karper L.P., Seibyl J.P. et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans // Psychotomimetic, perceptual, cognitive, and neuroendocrine responses // Arch Gen Psychiatry. – 1994. – Vol. 51 (3). – R. 199–214.
32.    Adler C.M., Malhotra A.K., Elman I. et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia // Am J Psychiatry. – 1999. – 156. – R. 1646 –1649.
33.    Egan T. M., Yang B., Bartlett K. R. The effects of organizational learning culture and job satisfaction on motivation to transfer learning and turnover intention // Human Resource Development Quarterly. – 2004. – Vol. 15 (3). – R. 279–301.
34.    Beneyto M., Meador-Woodruff J.H. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder // Neuropsychopharmacology. – 2008. – Vol. 33 (9). – R. 2175–2186. 
35.    Clinton S.M., Meador-Woodruff J.H. Abnormalities of the NMDA Receptorand Associated Intracellular Molecules in the Thalamus in Schizophreniaand Bipolar Disorder // Neuropsychopharmacology. – 2004. – Vol. 29. – R. 1353–1362.
36.    Lewis D.A., Hashimoto T, Volk D.W. Cortical inhibitory neurons and schizophrenia // Nature Rev Neurosci. – 2005. – Vol. 6. – R. 312–324.
37.    Gerdeman G, Lovinger D.M. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum // J Neurophysiol. – 2001. – Vol. 85 (1). – R. 468–471. 
38.    Cepeda N.J., Kramer A.F., Gonzalez de Sather J. C. Changes in executive control across the life span: examination of task-switching performance // Dev Psychol. – 2001. – Vol. 37. – R. 715–730. 
39.    Moghaddam B., Javitt D. From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatmentment // Neuropsychopharmacology Reviews. – 2012. – Vol. 37. – R. 4–15.
40.    URL: http://refdb.ru/look/2096134-p17.html (data obrashcheniya: 12.09.2015)
41.    Bading H., Ginty D.D., Greenberg M.E. Regulation of gene expression in hippocampal neurons by distinct calcium signaling pathways // Science. – 1993. – Vol. 260. – R. 181–186.
42.    Duman R.S., Aghajanian G.K. Synaptic dysfunction in depression: potential therapeutic targets //Science. – 2012. – Vol. 338 (6103). – R. 68–72.
43.    Prommer E.E. Ketamine for pain: an update of uses in palliative care // J Palliat Med. – 2012;15(4). – R. 474–483.
44.    Gilmour G., Pioli E.Y., Dix S.L. et al. Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for “NMDA antagonist modeling” of schizophrenia //Psychopharmacology (Berl). – 2009. – Vol. 205. – R. 203–216.
45.    Johnson J.W., Kotermanski S.E. Mechanism of action of memantine // Curr Opin Pharmacol. – 2006. – Vol. 6. – R. 61–67.
46.    Kotermanski S.E., Wood J.T., Johnson J.W. Memantine binding to a superficial site on NMDA receptors contributes to partial trapping // J Physiol. – 2009. – Vol. 587. – R. 4589–4604.
47.    Kotermanski S., Johnson J., Thiels E. Comparison of behavioral effects of the NMDA receptor channel blockers memantine and ketamine in rats // Pharmacol Biochem Behav. – 2013. – Vol. 109. – R. 67–76.
48.    Uribe E., Landaeta J.,Wix R., Eblen A. Memantine Reverses Social Withdrawal Induced by Ketamine in Rats // Exp Neurobiol. – 2013. – Vol. 22 (1). – R. 18–22. 
49.    De Lucena D., Fernandes B.S., Berk M. et al. Improvement of negative and positive symptoms in treatmentrefractory schizophrenia: A double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine // J Clin Psychiatry. 2009. – Vol. 70 (10). – P. 1416–1423. 
50.    Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: metaanalysis of randomized, placebo-controlled trials // J Psychiatr Res. – 2013, Sep. – Vol. 47 (9). – 1143e9. URL: http://dx.doi.org/10.1016/j.jpsychires.2013.04.013. Epub 2013 May 18. 
51.    Rezaei F., Mohammad-Karimi M., Seddighi S. et al. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized, double-blind, placebo-controlled study // J Clin Psychopharmacol. – 2013. – Vol. 33 (3). – P. 336–342.
52.    Jung Goo Lee, Sae Woom Lee et al. Adjunctive Memantine Therapy for Cognitive Impairment in Chronic Schizophrenia: A Placebo-Controlled Pilot Study // Psychiatry Investig. – 2012. – Vol. 9 (2). – R. 166–173.
53.    Mosolov S.N. Shkaly psikhometricheskoi otsenki simptomatiki shizofrenii i kontseptsiya pozitivnykh i negativnykh rasstroistv. – M.: Novyi tsvet, 2001.
54.    Kay S.R., Opler L.A., Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia // Schizophrenia Bulletin. – 1987. – Vol. 13. – P. 261–276.
55.    Zigmond A.S., Snaith R.P. The Hospital Anxiety and Depression scale // Acta Psychiatr. Scand. – 1983. – Vol. 67. – P. 361–370. 
56.    Kalyagin V.A., Ovchinnikova T.S. Logopsikhologiya: ucheb. posobie dlya stud. vyssh. ucheb. zavedenii. – M.: Akademiya, 2006. — 320 s.
57.    Guy W. ECDEU assessment manual for psychopharmacology, revised 1976 // Rockville, MD: National Institute of Mental Health. Psychopharmacology Research Branch. – 1976. – P. 217–222, 313–331.
58.    Allan R., Martin C.R. Can the Hospital Anxiety and Depression Scale be used in patients with schizophrenia? // J Eval Clin Pract. – 2009, Feb. – Vol. 15 (1). – P. 134–141.
59.    Kern R.S., Gold J.M., Dickinson D. et al. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study // Schizophr Res. – 2011. – Vol. 126 (1–3). – P. 124–131.
60.    Cynthia Z. Burton, Lea Vella, et al. Twamley Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia // Schizophr Res. – 2013, May. – Vol. 146 (0). P. 244–248.